Sector
PharmaceuticalsOpen
₹12.35Prev. Close
₹12.47Turnover(Lac.)
₹1.77Day's High
₹12.9Day's Low
₹12.0152 Week's High
₹34.752 Week's Low
₹12Book Value
₹-122.58Face Value
₹2Mkt Cap (₹ Cr.)
67.76P/E
1.05EPS
11.89Divi. Yield
020 Jan 2025
12:00 AM
EGM
2 Sep 2024
12:00 AM
AGM
Announcement Date: 02 Sep, 2024
19 Aug 2024
12:00 AM
BookCloser
6 Feb 2025
12:00 AM
Board Meeting
Agenda : Audited Result
| Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|
Equity Capital | 10.83 | 10.83 | 10.83 | 10.83 |
Preference Capital | 14.2 | 14.2 | 14.2 | 14.2 |
Reserves | -701.66 | -715.53 | -731.15 | -706 |
Net Worth | -676.63 | -690.5 | -706.12 | -680.97 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Revenue | 356.05 | 329.52 | 269.81 | 263.05 |
yoy growth (%) | 8.05 | 22.12 | 2.56 | -14.52 |
Raw materials | -186.52 | -186.89 | -154.15 | -166.02 |
As % of sales | 52.38 | 56.71 | 57.13 | 63.11 |
Employee costs | -55.79 | -52.52 | -48.26 | -42.38 |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Profit before tax | -28.28 | -23.06 | -25.22 | -103.76 |
Depreciation | -32.7 | -33.59 | -34.63 | -35.73 |
Tax paid | -0.32 | -2.46 | -0.75 | -0.89 |
Working capital | -9.72 | -14.89 | -20.1 | -383.71 |
Other operating items |
| Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 8.05 | 22.12 | 2.56 | -14.52 |
Op profit growth | 77.3 | 270.66 | -109.62 | -58.33 |
EBIT growth | 219.15 | -130.93 | -79.22 | -51.62 |
Net profit growth | 55.93 | -64.67 | -85.14 | 82.18 |
| Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|---|
Gross Sales | 502.25 | 410.96 | 397.71 | 270.57 | 267.2 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 502.25 | 410.96 | 397.71 | 270.57 | 267.2 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 57.99 | 72.43 | 24.28 | 10.16 | 13.68 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,767.2 | 134.52 | 4,23,770.54 | 1,181.05 | 0.76 | 5,985.33 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 5,960.5 | 76.3 | 1,58,175.47 | 594 | 0.5 | 2,297 | 513.62 |
Cipla Ltd CIPLA | 1,486.8 | 25.8 | 1,20,075.94 | 1,438.15 | 0.87 | 4,134.87 | 360.72 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,185.8 | 59.05 | 1,07,722.35 | 485 | 0.88 | 2,330 | 222.38 |
Mankind Pharma Ltd MANKIND | 2,439.5 | 51.93 | 1,00,425.74 | 416.38 | 0 | 2,396.57 | 334.17 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Managing Director & CEO
G Munjal
Executive Chairman
S R Mehta
Joint Managing Director
V R Mehta
Non-Exec & Non-Independent Dir
Himanshu Jain
Non-Exec & Non-Independent Dir
N R Munjal
Non-Exec & Non-Independent Dir
Rishav Mehta
Non-Exec. & Independent Dir.
Subhash Chander Galhotra
Non-Exec. & Independent Dir.
Anoop Michra
Non-Exec. & Independent Dir.
Jagvir Singh Ahluwalia
Non-Exec. & Independent Dir.
Bhupinder Singh
Non-Exec. & Independent Dir.
Subodh Gupta
Non-Exec. & Independent Dir.
Prabhat Khurana
Company Sec. & Compli. Officer
Puneet Khurana
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Ind-Swift Ltd
Summary
Ind-Swift Limited (ISL) is an India-based pharmaceutical company. The Company is engaged in the manufacturing and marketing of pharmaceutical finished dosage. The products manufactured by the company include cephalosporins, quinolones, aminoglycosides, macrolides, chloramphenicol, tetracyclines, sulphonamides, antianaerobics and anti-fungals. The company manufactures various dosage forms, including oral solutions and suspensions; dry syrups and hard gelatin capsules; tablets; dermatologicals comprising creams, ointments, and gels; eye and ear drops; and injectables. The company, through their different divisions, markets formulations focusing on the needs of various therapeutic segments, such as diabetology, cardiovascular, anesthesiology, oncology, ophthalmology, neuropsychiatry, gynecology, pediatric, ENT, surgery, internal medicine, dermatology, urology, cardiology, and dental specialty.Ind-Swift Limited was incorporated in June, 1986. In the year 1991, the company set up a manufacturing facility for injectables and eye/ear drops. In the year 1995, they incorporated Ind-Swift Laboratories Ltd for initiating a backward integration into the manufacturing of APIs and advanced intermediates.In the year 1997, the company commissioned a multipurpose plant with five independent blocks erected as per US FDA standards, designed by Quara, Switzerland. In addition, they launched a Marketing Division with the name Ind-Swift Health Care.In the year 2000, the company launched Super Spec
Read More
What is the Ind-Swift Ltd share price today?
The Ind-Swift Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹12.51 today.
What is the Market Cap of Ind-Swift Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Ind-Swift Ltd is ₹67.76 Cr. as of 09 May ‘25
What is the PE and PB ratio of Ind-Swift Ltd?
The PE and PB ratios of Ind-Swift Ltd is 1.05 and -0.10 as of 09 May ‘25
What is the 52 Week High and Low of Ind-Swift Ltd?
The 52-week high/low is the highest and lowest price at which a Ind-Swift Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Ind-Swift Ltd is ₹12 and ₹34.7 as of 09 May ‘25
What is the CAGR of Ind-Swift Ltd?
Ind-Swift Ltd's CAGR for 5 Years at 39.62%, 3 Years at 5.90%, 1 Year at -45.78%, 6 Month at -46.80%, 3 Month at -17.91% and 1 Month at -5.39%.
What is the shareholding pattern of Ind-Swift Ltd?
The shareholding pattern of Ind-Swift Ltd is as follows:
Promoters - 55.58 %
Institutions - 0.00 %
Public - 44.42 %
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
